Menu
Search
|

Menu

Close
X

Trovagene Inc TROV.OQ (NASDAQ Stock Exchange Capital Market)

0.75 USD
-- (--)
As of Jul 19
chart
Previous Close 0.75
Open --
Volume --
3m Avg Volume 82,902
Today’s High --
Today’s Low --
52 Week High 13.32
52 Week Low 0.72
Shares Outstanding (mil) 37.27
Market Capitalization (mil) 31.68
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.00 Mean rating from 2 analysts

KEY STATS

Revenue (mm, USD)
FY18
0
FY17
1
FY16
0
FY15
0
EPS (USD)
FY18
-1.039
FY17
-9.178
FY16
-15.614
FY15
-13.051
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.76
Price to Sales (TTM)
vs sector
89.43
5.73
Price to Book (MRQ)
vs sector
7.52
5.47
Price to Cash Flow (TTM)
vs sector
--
23.29
Total Debt to Equity (MRQ)
vs sector
46.84
16.84
LT Debt to Equity (MRQ)
vs sector
0.00
12.51
Return on Investment (TTM)
vs sector
-144.44
14.61
Return on Equity (TTM)
vs sector
-204.02
16.34

EXECUTIVE LEADERSHIP

Thomas Adams
Chairman of the Board, Interim Chief Executive Officer, Since 2018
Salary: --
Bonus: --
Athena Countouriotis
Director, Since 2017
Salary: --
Bonus: --
Paul Billings
Independent Director, Since 2013
Salary: --
Bonus: --
John Brancaccio
Independent Director, Since 2005
Salary: --
Bonus: --
Gary Jacob
Independent Director, Since 2009
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Medical Equipment, Supplies & Distribution
Address:

11055 Flintkote Ave
SAN DIEGO   CA   92121-1220

Phone: +1858.2175420

Trovagene, Inc. is a clinical-stage, precision medicine oncology therapeutics company. The Company’s lead drug candidate, PCM-075, is a Polo-like Kinase 1 (PLK1) selective adenosine triphosphate (ATP) competitive inhibitor. PCM-075 has shown preclinical antitumor activity as a single agent and in synergy combinations with more than ten different chemotherapeutics and targeted therapies, such as Zytiga (abiraterone acetate), Beleodaq (belinostat), Quizartinib (AC220), a development stage FLT3 inhibitor, and Velcade (bortezomib) in Acute Myeloid Leukemia (AML), metastatic Castration-Resistant Prostate Cancer (mCRPC) and other liquid and solid tumor cancers. PCM-075 developed high selectivity to PLK1, to be administered orally, and to have a relatively short drug half-life of approximately 24 hours compared to other PLK inhibitors. PCM-075 has completed a safety study in patients with advanced metastatic solid tumors with a phase Ib/II clinical trial in patients with AML underway.

SPONSORED STORIES